Product image of Ivabalan (Ivabradine) supplied by GNH India

Ivabalan

Active Ingredient:
Ivabradine
Origin:
EU

Ivabalan (Ivabradine)

Ivabradine, the active ingredient in Ivabalan, is a If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate and is employed in the management of chronic stable angina and heart failure with reduced ejection fraction in adult patients. The drug selectively inhibits the funny current in the sino‑atrial node, lowering heart rate without compromising myocardial contractility, which helps relieve angina symptoms and improve functional capacity in heart failure.

GNH India supplies Ivabalan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Tad Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ivabradine is used to manage conditions where heart‑rate reduction is therapeutic, particularly within the cardiovascular disease spectrum.

  • Chronic stable angina: lowers heart rate to decrease myocardial oxygen demand and relieve chest pain.
  • Heart failure with reduced ejection fraction: improves left‑ventricular function and exercise capacity by controlling heart rate.
  • Elevated resting heart rate despite beta‑blocker therapy: provides additional rate control when beta‑blockers alone are insufficient.

How It Works

  • Ivabradine selectively binds to the HCN (hyperpolarization‑activated cyclic nucleotide‑gated) channels that generate the funny (If) current in the sino‑atrial node. By inhibiting this current, the drug slows spontaneous depolarisation, reducing heart rate while preserving myocardial contractility and blood pressure, thereby decreasing cardiac workload and oxygen consumption.

Side Effects

Ivabradine may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects

  • Bradycardia: symptomatic slowing of heart rate.
  • Visual disturbances (phosphenes): transient luminous phenomena.
  • Headache: mild to moderate intensity.
  • Dizziness: often related to reduced heart rate.
  • Fatigue: general feeling of tiredness.
  • Blurred vision: occasional visual acuity changes.

Serious or Rare Side Effects

  • Severe bradycardia: may require medical intervention.
  • Atrial fibrillation: irregular heart rhythm episodes.
  • Symptomatic hypotension: low blood pressure causing faintness.
  • Heart block: impaired electrical conduction requiring monitoring.

Precautions & Warnings

When prescribing Ivabradine, clinicians should observe several precautionary measures to ensure safe use.

  • Monitor heart rate: ensure resting rate remains above the recommended minimum.
  • Avoid in severe hepatic impairment: reduced metabolism may increase exposure.
  • Caution in patients with sick sinus syndrome: risk of excessive bradycardia.
  • Do not combine with other strong bradycardic agents: additive effects may occur.
  • Avoid strong CYP3A4 inhibitors: may raise plasma concentrations.
  • Store below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Ivabradine can interact with other medicines, affecting its plasma concentration or additive pharmacodynamic effects.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase ivabradine levels.
  • Concomitant use with other bradycardic agents (e.g., beta‑blockers, digoxin): risk of excessive heart‑rate reduction.

Moderate Interactions (Monitor Closely)

  • Moderate CYP3A4 inhibitors (e.g., erythromycin, diltiazem): may require dose adjustment.
  • Drugs that prolong QT interval: combined effect could increase arrhythmia risk.
  • Antihypertensive agents: monitor blood pressure for additive hypotensive effect.

Frequently Asked Questions

Ivabalan contains ivabradine and is indicated for chronic stable angina and for heart failure with reduced ejection fraction. In both conditions the drug lowers heart rate, helping to reduce myocardial oxygen demand and improve functional capacity.

Ivabradine selectively inhibits the funny (If) current in the sino‑atrial node by binding to HCN channels. This slows the spontaneous depolarisation of pacemaker cells, reducing heart rate without affecting contractility or blood pressure.

The dose of Ivabalan is individualized. A qualified prescriber determines the appropriate strength, frequency and titration based on the patient’s clinical condition, heart‑rate response and tolerability.

Safety data for ivabradine in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

To order Ivabalan, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by directly inhibiting the If current without affecting beta‑adrenergic receptors. This can be advantageous when beta‑blockers are contraindicated, not tolerated, or when additional rate control is needed beyond beta‑blockade.

Store Ivabalan below 25 °C in its original packaging, protected from moisture and direct light. Do not store in a bathroom or near heat sources, and keep the container tightly closed to maintain product stability.

Ivabalan is taken orally, usually with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless otherwise instructed.

The most serious risks include severe bradycardia, atrial fibrillation, symptomatic hypotension and heart block. Patients should be monitored for signs of excessive heart‑rate reduction, arrhythmias or low blood pressure, especially during dose initiation or when combined with other rate‑lowering agents.

Ivabalan should be avoided in patients with severe hepatic impairment, sick sinus syndrome, second‑ or third‑degree atrioventricular block, uncontrolled hypotension, or in those taking strong CYP3A4 inhibitors that cannot be discontinued. Contraindications are confirmed by the prescribing physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ivabradine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT